MIT News · September 24, 2026 · Research stage · Dr. Mohan's take
The value of this collector is that it gives us living cells from a precise region of tissue while keeping the specimen available for routine pathology. In the researchers' test on excised fallopian tubes, those cells grew into organoids - living models that could let us study disease and eventually test treatment responses from an individual patient's sample. That link between the slide and a living model is the exciting part. It is still early research, not a proven ovarian-cancer screening test or a clinical drug-selection method.
A short response to MIT News, not a copy. Tested on tissue removed from patients; in-patient sampling, screening and treatment selection remain future possibilities. Not medical advice.
← More from Doctor's Doc MD